Form 4: Cyclo Therapeutics Director William S. Shanahan Receives Stock and Options as Compensation

Director William S. Shanahan received shares and options from Cyclo Therapeutics as part of the company's compensation policy.

Summary

• William S. Shanahan, a director at Cyclo Therapeutics, Inc., reported changes in beneficial ownership on June 3, 2024.
• Shanahan received 7,813 shares of common stock as compensation in lieu of cash, valued at $1.28 per share.
• He also acquired options to purchase 15,562 shares of common stock at an exercise price of $1.28, vesting over one year in equal quarterly installments.
• Following these transactions, Shanahan directly owns 125,744 shares of common stock and options for 15,562 shares.

Sentiment

Score: 6

Explanation: The document reflects standard compensation practices. It's neutral from an investment perspective, indicating alignment of interests but not necessarily a driver of significant positive or negative sentiment.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule for the options incentivizes continued service and contribution to the company.

Industry Context

Director compensation through stock and options is a common practice in the biotechnology industry to align management's interests with shareholders and incentivize long-term growth.

Stakeholder Impact

• Shareholders may view the stock and option grants as a positive sign, aligning director interests with company performance.
• Employees may see this as a standard compensation practice for directors.

Key Dates